SUBSCRIBE
SUBSCRIBE

Sage Therapeutics

Roche Could Take a $500M Hit Over Patent Losses
Biotech Bay
Sage Therapeutics Fills Its Pockets
Sage Therapeutics has been on a roll with good news lately.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
Ignyta Stock Booms on Promising Mid-Stage Lung Can
Drug Development
ASH Heats Up, Plus Alkermes’ Huge I-Told-Ya-So
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
Drug Development
Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression
The positive results support the company’s planned regulatory submissions.
November 9, 2017
 · 
2 min read
 · 
Mark Terry
Drug Development
Does SAGE Therapeutics’ Failure Predict Its Future Results?
September 13, 2017
 · 
1 min read
SAGE Therapeutics Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test
Drug Development
SAGE Therapeutics Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test
September 12, 2017
 · 
2 min read
Drug Development
SAGE Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain Drugs
February 22, 2017
 · 
1 min read
SAGE Therapeutics Crashes Hard as Lead Epilepsy Drug Flunks Phase III Test
Business
SAGE Therapeutics Boss Gets Overenthusiastic About Drug, Walks Back Discussion of M&A Activity
February 17, 2017
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
SAGE Therapeutics’ Stock Explodes as Drug Eliminates Postpartum Depression in Mid-Stage Study
July 12, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
10 Biotech Stocks that Could Blow Up in Q3
July 6, 2016
 · 
3 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Genetown
Sage Therapeutics to Present at Upcoming May Investor Conferences
April 28, 2021
 · 
1 min read
Business
Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
April 20, 2021
 · 
1 min read
Business
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
April 12, 2021
 · 
15 min read
Genetown
Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day
March 24, 2021
 · 
1 min read
Genetown
Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD
March 17, 2021
 · 
11 min read
Business
Sage Therapeutics Announces Departure of Chief Operating Officer
March 16, 2021
 · 
4 min read
Business
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
February 24, 2021
 · 
23 min read
Genetown
Sage Therapeutics to Present at Upcoming Investor Conferences
February 11, 2021
 · 
1 min read
Business
Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
February 10, 2021
 · 
1 min read
Genetown
Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference
January 7, 2021
 · 
10 min read
Load More